Reportlinker Adds The Top 10 Eastern European Pharmaceutical Companies: Growth strategies, performance and SWOT analyses

NEW YORK, April 1 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Top 10 Eastern European Pharmaceutical Companies: Growth strategies, performance and SWOT analyses

http://www.reportlinker.com/p0185309/The-Top-10-Eastern-European-Pharmaceutical-Companies-Growth-strategies-performance-and-SWOT-analyses.html

The Eastern European pharmaceutical companies comprise both Eastern Europe-based and MNCs. This chapter provides an insight into the current state of Eastern European pharmaceutical industry as well as the evolving trends. It also provides the competitive landscape of the industry based on financial and operational (revenue growth over the last five years, exposure to major markets and presence in major therapeutic areas) parameters in the Eastern European region.

The report also includes profiles of the top ten companies in the region and also gives a brief summary of top 11 to 20 players. The top 10 companies in the Eastern European pharmaceutical industry were assessed on following parameters:

• Each company's market share in the Eastern European pharmaceutical market;
• Each company's marketed products, geographic and therapeutic focus;
• Each company's growth strategies and major acquisitions and divestments in this market;
• Key mergers and acquisitions formed by these companies;
• Business-related strengths and weaknesses of these companies, and insights into the opportunities and threats facing them.

Key features of this report

• Market dynamics of the Eastern European pharmaceutical market during the period 2004-08.
• Key market drivers and resistors.
• Trends of the Eastern European pharmaceutical market.
• Identification of the top 10 players in the Eastern European pharmaceutical market .
• Company analysis and market share of the top 10 players in the Eastern European pharmaceutical market.

Scope of this report

• Learn from the strategies of the Eastern European pharmaceutical companies to target future growth markets effectively, avoid their mistakes, replicate their successes and learn of the threats they face.
• Benchmark your performance against the leading Eastern European pharmaceutical companies using market share data by company and comprehending their strategies.
• Understand the major issues affecting the Eastern European pharmaceutical market.
• Predict the key growth areas in the Eastern European pharmaceuticals market arising from the government's initiative to promote generics in the region.

Key Market Issues

• Parallel trade: Increasing incidence of parallel traded products will impact companies operating in the region resulting in potential loss of sales eventually affecting cash flows and bringing down innovation in drug development.
• Complex pricing: Complex drug pricing, reimbursement and purchasing policies will affect the development of new drugs thus affecting the growth of Eastern European pharmaceutical market.
• Insufficient funds: Inadequate funding from the government may slowdown the development of the pharmaceutical industry in Eastern Europe.
• Regulatory hurdles: Increasing due diligence and compliance with standards leads to cost overrun and delay in new product launches.

Key findings from this report

• The Eastern European market is valued at $25,417m as of 2008, which is an increase of 19.9% over 2007. The industry witnessed a CAGR of 19.6% during 2004–08.
• Poland, Russia and Hungary lead the Eastern European pharmaceutical market and together contributed 62.1% of total market value in 2008.
• Novartis lead the Eastern European pharmaceutical market with a market share of 7.1% in 2008, followed by Sanofi-Aventis (6.1%) and GSK (4.9%).
• Parallel trade in Eastern Europe plays an important role influencing the multi-nationals' branded products, which results in potential loss of sales and brings down the activity of innovative drug development.

Key questions answered

• What was the market size of the Eastern European pharmaceutical market in 2008?
• What are the trends in the Eastern European pharmaceutical market?
• Who are the top 10 players in the market?
• What is the market share of each of the companies?
• What are the growth strategies of the top 10 companies?

Companies mentioned

Table of Contents

The Top 10 Eastern European Pharmaceutical Companies

Executive summary 14

Industry overview 14

Novartis 15

Sanofi-Aventis 15

GlaxoSmithKline (GSK) 16

Servier 16

Roche 17

Pfizer 17

Bayer 18

Teva 18

Zentiva 19

Krka 19

Chapter 1 Introduction 22

What is this report about? 22

Methodology 22

Chapter 2 Industry overview 24

Summary 24

Introduction 25

Market dynamics 25

Eastern European market: size and growth 25

Parallel trade in Eastern Europe 27

Key market drivers and resistors 28

Competitive landscape 29

Competitive position of the top 10 companies 29

Comparative analysis of the top 10 companies 31

Trends 33

Consolidation underway 33

Increasing use of generics 33

Rise of value added generics and biosimilars 34

Cancer market represents strong commercial opportunity 35

Increasing presence of biotechnology 35

Chapter 3 Novartis 38

Summary 38

Company overview 39

Geographic focus 39

Marketed products 40

Therapeutic focus 40

Research and development 41

Growth strategies 42

Focus on biosimilars 42

Strengthening its oncology portfolio 42

Strengthening presence in Romania 43

Growing business by forging alliances and partnerships 43

Acquisitions and divestments 44

SWOT analysis 45

Chapter 4 Sanofi-Aventis 48

Summary 48

Company overview 49

Geographic focus 49

Marketed products 51

Therapeutic focus 52

Research and development 52

Growth strategies 53

Focusing on external collaborations for business development 53

Acquisitions and divestments 54

SWOT analysis 55

Chapter 5 GSK 58

Summary 58

Company overview 59

Geographic focus 59

Marketed products 61

Therapeutic focus 62

Research and development 62

Growth strategies 63

Investing in product capabilities and R&D 63

Partnerships fostering growth 64

Expanding product portfolio through new drug launches 64

Acquisitions and divestments 65

SWOT analysis 66

Chapter 6 Servier 68

Summary 68

Company overview 69

Geographic focus 69

Marketed products 71

Therapeutic focus 72

Research and development 72

Growth strategies 73

Expanding production capacity and establishing innovative drug development centers 73

Partnerships and alliances to fuel growth 73

Acquisitions and divestments 74

SWOT analysis 75

Chapter 7 Roche 78

Summary 78

Company overview 79

Geographic focus 79

Marketed products 81

Therapeutic focus 82

Research and development 82

Growth strategies 83

Sustaining sales growth for major oncology franchises through lineextensions 83

Diversifying into new therapeutic areas beyond oncology 84

Acquisitions and divestments 84

SWOT analysis 85

Chapter 8 Pfizer 88

Summary 88

Company overview 89

Geographic focus 89

Marketed products 91

Therapeutic focus 92

Research and development 92

Growth strategies 94

Expanding in the under-penetrated Russian market 94

Acquisitions and divestments 94

SWOT analysis 95

Chapter 9 Bayer 98

Summary 98

Company overview 99

Geographic focus 99

Marketed products 101

Therapeutic focus 102

Research and development 102

Growth strategies 103

Realigning focus in healthcare to improve long-term profitability 103

New product development to drive margins in Eastern Europe 104

Acquisitions and divestments 105

SWOT analysis 106

Chapter 10 Teva 108

Summary 108

Company overview 109

Geographic focus 109

Marketed products 110

Therapeutic focus 111

Research and development 111

Growth strategies 112

Leveraging the biosimilar opportunity in Europe 112

Investing in niche specialty areas to drive growth 113

Acquisitions and divestments 113

SWOT analysis 114

Chapter 11 Zentiva 116

Summary 116

Company overview 117

Geographic focus 117

Marketed products 119

Therapeutic focus 120

Research and development 120

Growth strategies 121

Strengthening geographical footprint 121

Improving efficiency to drive profitable growth 122

Acquisitions and divestments 122

SWOT analysis 123

Chapter 12 Krka 126

Summary 126

Company overview 127

Geographic focus 127

Marketed products 129

Therapeutic focus 130

Research and development 130

Growth strategies 131

New product launches fostering growth 131

Expanding production capacity of tablets and injectables and investing in

R&D 132

Fortifying its vertical integrated business to cut manufacturing costs 133

Acquisitions and divestments 133

SWOT analysis 134

Chapter 13 11–20 companies 136

AstraZeneca 136

Company overview 136

Geographic focus 136

Marketed products 137

Therapeutic focus 138

Research and development 140

Gedeon Richter 140

Company overview 140

Geographic focus 141

Marketed products 142

Therapeutic focus 142

Research and development 143

Menarini 144

Company overview 144

Geographic focus 144

Marketed products 146

Therapeutic focus 146

Research and development 147

Schering-Plough 148

Company overview 148

Geographic focus 148

Marketed products 150

Therapeutic focus 150

Research and development 152

Johnson & Johnson (J&J) 152

Company overview 152

Geographic focus 153

Marketed products 155

Therapeutic focus 155

Research and development 157

Eli Lilly 157

Company overview 157

Geographic focus 158

Marketed products 158

Therapeutic focus 159

Research and development 161

Polpharma 162

Company overview 162

Geographic focus 162

Marketed products 163

Therapeutic focus 163

Research and development 164

Boehringer Ingelheim 165

Company overview 165

Geographic focus 165

Marketed products 166

Therapeutic focus 168

Research and development 169

Novo Nordisk 169

Company overview 169

Geographic focus 170

Marketed products 171

Therapeutic focus 171

Research and development 172

Merck & Co. 173

Company overview 173

Geographic focus 173

Marketed products 175

Therapeutic focus 176

Research and development 177

Chapter 14 Appendix 180

Glossary 180

Index 183

List of Figures

Figure 2.1: Eastern European pharmaceutical market size, 2004–08 26

Figure 2.2: Market position of the Eastern European pharmaceutical companies, 2008 27

Figure 2.3: Key market drivers and resistors of Eastern European pharmaceutical market 29

Figure 2.4: Top 10 pharmaceutical companies in Eastern Europe market share, 2008 30

Figure 2.5: Comparative analysis of top 10 companies 32

Figure 3.6: Novartis geographic focus, 2007–08 39

Figure 3.7: Novartis therapeutic focus, 2007–08 41

Figure 3.8: Novartis SWOT analysis 45

Figure 4.9: Sanofi-Aventis geographic focus, 2007–08 50

Figure 4.10: Sanofi-Aventis therapeutic focus, 2007–08 52

Figure 4.11: Sanofi-Aventis SWOT analysis 55

Figure 5.12: GSK geographic focus, 2007–08 60

Figure 5.13: GSK therapeutic focus, 2007–08 62

Figure 5.14: GSK SWOT analysis 66

Figure 6.15: Servier geographic focus, 2007–08 70

Figure 6.16: Servier therapeutic focus, 2007–08 72

Figure 6.17: Servier SWOT analysis 75

Figure 7.18: Roche geographic focus, 2007–08 80

Figure 7.19: Roche therapeutic focus, 2007–08 82

Figure 7.20: Roche SWOT analysis 85

Figure 8.21: Pfizer geographic focus, 2007–08 90

Figure 8.22: Pfizer therapeutic focus, 2007–08 92

Figure 8.23: Pfizer SWOT analysis 95

Figure 9.24: Bayer HealthCare geographic focus, 2007–08 100

Figure 9.25: Bayer HealthCare therapeutic focus, 2007–08 102

Figure 9.26: Bayer HealthCare SWOT analysis 106

Figure 1.1: Teva geographic focus, 2007–08 109

Figure 10.28: Teva therapeutic focus, 2007–08 111

Figure 10.29: Teva SWOT analysis 114

Figure 11.30: Zentiva therapeutic focus, 2007–08 118

Figure 11.31: Zentiva therapeutic focus, 2007–08 120

Figure 11.32: Zentiva SWOT analysis 123

Figure 12.33: Krka geographic focus, 2007–08 128

Figure 12.34: Krka therapeutic focus, 2007–08 130

Figure 12.35: Krka SWOT analysis 134

Figure 13.36: AstraZeneca geographic focus, 2007–08 137

Figure 13.37: AstraZeneca therapeutic focus, 2007–08 139

Figure 13.38: Gedeon Richter geographic focus, 2007–08 141

Figure 13.39: Gedeon Richter therapeutic focus, 2007–08 143

Figure 13.40: Menarini geographic focus, 2007–08 145

Figure 13.41: Menarini therapeutic focus, 2007–08 147

Figure 13.42: Schering-Plough geographic focus, 2007–08 149

Figure 13.43: Schering-Plough therapeutic focus, 2007–08 151

Figure 13.44: J&J geographic focus, 2007–08 154

Figure 13.45: J&J therapeutic focus, 2007–08 156

Figure 13.46: Eli Lilly geographic focus, 2007–08 158

Figure 13.47: Eli Lilly therapeutic focus, 2007–08 160

Figure 13.48: Polpharma therapeutic focus, 2007–08 164

Figure 13.49: Boehringer Ingelheim geographic focus, 2007–08 166

Figure 13.50: Boehringer Ingelheim therapeutic focus, 2007–08 168

Figure 13.51: Novo Nordisk geographic focus, 2007–08 170

Figure 13.52: Novo Nordisk therapeutic focus, 2007–08 172

Figure 13.53: Merck & Co. geographic focus, 2007–08 174

Figure 13.54: Merck & Co. therapeutic focus, 2007–08 176

List of Tables

Table 2.1: Eastern European pharmaceutical market size ($m), 2004–08 25

Table 2.2: Top 10 pharmaceutical companies in Eastern Europe growth (%), 2004–08 31

Table 2.3: Select M&A in Eastern Europe, 2007–09 33

Table 2.4: Select product launches in oncology in Eastern Europe, 2007–08 35

Table 2.5: Presence of biotechnology products in Eastern Europe 36

Table 3.6: Novartis snapshot 38

Table 3.7: Novartis top 10 marketed products sales ($m), 2007–08 40

Table 3.8: Novartis late stage R&D pipeline 42

Table 3.9: Novartis acquisitions and divestments, 2007–09 44

Table 4.10: Sanofi-Aventis snapshot 48

Table 4.11: Sanofi-Aventis top 10 marketed products sales ($m), 2007–08 51

Table 4.12: Sanofi-Aventis late stage R&D pipeline 53

Table 5.13: GSK snapshot 58

Table 5.14: GSK top 10 marketed products sales ($m), 2007–08 61

Table 5.15: GSK late stage R&D pipeline 63

Table 5.16: Select GSK new drug launches, 2007–09 65

Table 6.17: Servier snapshot 68

Table 6.18: Servier top 10 marketed products sales ($m), 2007–08 71

Table 6.19: Servier partnerships and alliances, 2007–09 74

Table 7.20: Roche snapshot 78

Table 7.21: Roche top 10 marketed products sales ($m), 2007–08 81

Table 7.22: Roche late stage R&D pipeline 83

Table 7.23: Roche late stage pipeline products 84

Table 8.24: Pfizer snapshot 88

Table 8.25: Pfizer top 10 marketed products sales ($m), 2007–08 91

Table 8.26: Pfizer's phase III R&D pipeline 93

Table 9.27: Bayer HealthCare snapshot 98

Table 9.28: Bayer HealthCare top 10 marketed products sales ($m), 2007–08 101

Table 9.29: Bayer HealthCare late stage R&D pipeline 103

Table 9.30: Select Bayer HealthCare's product pipeline, 2007–09 105

Table 10.31: Teva snapshot 108

Table 10.32: Teva top 10 marketed products sales ($m), 2007–08 110

Table 10.33: Teva's phase III R&D pipeline 112

Table 10.34: Select Teva's development pipeline in niche specialty areas 113

Table 11.35: Zentiva snapshot 116

Table 11.36: Zentiva top 10 marketed products sales ($m), 2007–08 119

Table 11.37: Select Zentiva new product launches, 2007–08 121

Table 12.38: Krka snapshot 126

Table 12.39: Krka top 10 marketed products sales ($m), 2007–08 129

Table 12.40: Select Krka new drug launches, 2007–09 131

Table 13.41: AstraZeneca snapshot 136

Table 13.42: AstraZeneca top 10 marketed products sales ($m), 2007–08 138

Table 13.43: AstraZeneca late stage R&D pipeline 140

Table 13.44: Gedeon Richter snapshot 140

Table 13.45: Gedeon Richter top 10 marketed products sales ($m), 2007–08 142

Table 13.46: Menarini snapshot 144

Table 13.47: Menarini top 10 marketed products sales ($m), 2007–08 146

Table 13.48: Schering-Plough snapshot 148

Table 13.49: Schering-Plough top 10 marketed products sales ($m), 2007–08 150

Table 13.50: Schering-Plough's phase III R&D pipeline 152

Table 13.51: J&J snapshot 152

Table 13.52: J&J top 10 marketed products sales ($m), 2007–08 155

Table 13.53: J&J's phase III R&D pipeline 157

Table 13.54: Eli Lilly snapshot 157

Table 13.55: Eli Lilly top 10 marketed products sales ($m), 2007–08 159

Table 13.56: Eli Lilly's phase III R&D pipeline 161

Table 13.57: Polpharma snapshot 162

Table 13.58: Polpharma top 10 marketed products sales ($m), 2007–08 163

Table 13.59: Boehringer Ingelheim snapshot 165

Table 13.60: Boehringer Ingelheim top 10 marketed products sales ($m), 2007–08 167

Table 13.61: Boehringer Ingelheim's phase III R&D pipeline 169

Table 13.62: Novo Nordisk snapshot 169

Table 13.63: Novo Nordisk top 10 marketed products sales ($m), 2007–08 171

Table 13.64: Novo Nordisk phase III R&D pipeline 172

Table 13.65: Merck & Co. snapshot 173

Table 13.66: Merck & Co. top 10 marketed products sales ($m), 2007–08 175

Table 13.67: Merck & Co's phase III R&D pipeline 177

To order this report:

Pharmaceutical Industry: The Top 10 Eastern European Pharmaceutical Companies: Growth strategies, performance and SWOT analyses

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker